The capital injection stems from the elritercept license agreement, a development Keros had signaled to investors back in July. Having secured the funds, the company’s board greenlit the buyback, granting management the flexibility to repurchase outstanding shares through open market transactions or other legal channels. This move marks a pivot toward returning value to shareholders while the firm continues its progress through the clinical-stage pipeline.